Revvity Inc. (RVTY)

NYSE: RVTY · Real-Time Price · USD

94.00

0.57 (0.61%)

At close: May 01, 2025, 11:53 AM

0.61% (1D)

Bid	93.92
Market Cap	11.29B
Revenue (ttm)	2.77B
Net Income (ttm)	309.38M
EPS (ttm)	2.41
PE Ratio (ttm)	39
Forward PE	17.03
Analyst	Buy

Ask	94.09
Volume	538,089
Avg. Volume (20D)	1,193,591
Open	94.89
Previous Close	93.43
Day's Range	91.18 - 94.80
52-Week Range	88.53 - 129.50
Beta	1.07

About RVTY

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences resea...

Sector Healthcare

IPO Date Jul 6, 1965

Employees 11,000

Stock Exchange NYSE

Ticker Symbol RVTY

Website https://www.perkinelmer.com

Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for RVTY stock is "Buy." The 12-month stock price forecast is $125, which is an increase of 32.99% from the latest price.

Stock Forecasts

Earnings Surprise

Revvity has released their quartely earnings on Apr 28, 2025:

Revenue of $664.76M exceeds estimates by $3.58M, with 2.28% YoY growth.

EPS of 1.01 exceeds estimates by 0.06, with 3.06% YoY growth.

Why Price Moved

2 days ago

+0.82%

RVTY stock has given up its prior gain. Revvity sh... Unlock content with Pro Subscription

3 days ago

+0.82%

Revvity shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates.

News

3 days ago · zacks.com

RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up

Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.

3 days ago · seekingalpha.com

Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript

Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chie...

2 days ago · zacks.com

Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare t...

2 days ago · benzinga.com

Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop

Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.

2 days ago · zacks.com

Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates

Revvity (RVTY) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.98 per share a year ago.

2 days ago · reuters.com

Revvity beats quarterly estimates on steady demand for medical equipment

Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for d...

2 days ago · businesswire.com

Revvity Announces Financial Results for the First Quarter of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as comp...

6 days ago · zacks.com

Why Revvity (RVTY) Could Beat Earnings Estimates Again

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

5 days ago · zacks.com

Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?

RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.

6 days ago · businesswire.com

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2...

Load More News